for people ages 18 years and up (full criteria)
at Stanford, California and other locations
study started



The primary objective of this study is to generate evidence demonstrating the domain specification (via modern psychometric methods), reliability, validity, and responsiveness (within-subject meaningful change) of the Patient-Reported Outcome (PRO) endpoints.

Official Title

A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avi


Participants will also complete the EXAcerbations of Chronic Pulmonary Disease Tool (EXACT), EXACT Respiratory Symptoms (EXACT-RS), St. George Respiratory Questionnaire (SGRQ), Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-Fatigue), Patient Global Impression of Severity - Respiratory (PGIS-Respiratory), and Patient Global Impression of Severity - Fatigue (PGIS-Fatigue) at baseline and throughout the study as anchors for the validation of the QoL-B and PROMIS F-SF 7a.


Mycobacterium Infections, Nontuberculous, Nontuberculous Mycobacterial Lung Infection, Mycobacterium avium complex, Psychometric validation, Patient-reported outcome, Infections, Communicable Diseases, Mycobacterium Infections, Nontuberculous Mycobacterium Infections, Azithromycin, Amikacin, Ethambutol, ALIS, ELC


You can join if…

Open to people ages 18 years and up

  • Male or female, ≥ 18 years of age (19 years or older in South Korea)
  • Current diagnosis of Mycobacterium avium Complex (MAC) lung infection
  • Positive sputum culture for MAC within 6 months prior to screening
  • A chest computed tomography (CT) scan, read locally, within 6 months prior to Screening to determine presence and size of pulmonary cavities. Participants who do not have a chest CT scan within 6 months prior to Screening will be required to obtain a chest CT scan, read locally, during Screening
  • Willingness and ability to adhere to prescribed study treatment during the study
  • Ability to produce (spontaneously or with induction) approximately 2 mL of sputum for mycobacteriology at Screening
  • Women of child-bearing potential (WOCBP) (ie, fertile following menarche and until becoming post-menopausal unless permanently sterile) and fertile men (ie, all men after puberty unless permanently sterile by bilateral orchidectomy) agree to practice a highly effective method of birth control from Day 1 to at least 90 days after the last dose. Examples of such birth controls are:
    • true abstinence (refraining from heterosexual intercourse during the entire study),
    • copper intrauterine device (IUD),
    • hormonal methods (levonorgestrel-releasing intrauterine system, progestogen implant, combined oral contraceptive pill [combined with barrier method]),
    • exclusive homosexual relationship, or
    • sole male partner who has undergone surgical sterilization with confirmation of azoospermia at least 3 months post procedure while participating in the study
  • Provide signed informed consent prior to administration of study drugs or performing any study related procedure
  • Be able to comply with study drugs use, study visits, and study procedures as defined by the protocol
  • Men with partners who are WOCBP (pregnant or non-pregnant) agree to use condoms and non-pregnant partners should practice a highly effective method of birth control

You CAN'T join if...

  • Diagnosis of cystic fibrosis (CF)
  • History of more than 3 MAC lung infections
  • Received any mycobacterial antibiotic treatment for current MAC lung infection
  • Refractory MAC lung infection, defined as having positive MAC cultures while being treated with a multidrug mycobacterial antibiotic treatment regimen for a minimum of 6 consecutive months and no documented successful treatment, defined as negative sputum culture for MAC and cessation of treatment
  • Relapse of prior MAC lung infection, defined as positive sputum culture for MAC ≤ 6 months of cessation of prior successful treatment
  • Evidence of any pulmonary cavity ≥ 2 cm in diameter, as determined by chest CT scan, read locally, within 6 months prior to Screening
  • Radiographic finding of new lobar consolidation, atelectasis, significant pleural effusion, or pneumothorax during routine clinical care within 2 months prior to Screening
  • Active pulmonary malignancy (primary or metastatic) or any malignancy requiring chemotherapy or radiation therapy within 1 year prior to Screening or anticipated during the study
  • Acute pulmonary exacerbation (eg, chronic obstructive pulmonary disease [COPD] or bronchiectasis) requiring treatment with antibiotics, or corticosteroids (intravenous [IV] or oral), within 4 weeks prior to and during Screening
  • Current smoker
  • History of lung transplantation
  • Prior exposure to amikacin liposome inhalation suspension (ALIS) (including clinical study)
  • Known hypersensitivity or contraindications to use to ALIS, aminoglycosides, or any of their excipients
  • Disseminated MAC infection
  • Positive pregnancy test or lactation at Screening. All WOCBP will be tested. Women not of childbearing potential are defined as postmenopausal (ie, amenorrheic for 12 months without an alternative medical cause or confirmed by more than one follicle stimulating hormone [FSH] measurement), or naturally or surgically sterile through bilateral oophorectomy, hysterectomy, or bilateral salpingectomy. For women under the age of 45 years, confirmatory testing with FSH should be considered
  • Administration of any investigational drug within 8 weeks prior to Screening
  • Known or suspected acquired immunodeficiency syndromes (HIV-positive, regardless of CD4 counts). Other immunodeficiency syndromes that may interfere with study participation in the opinion of the Investigator.
  • Current alcohol, medication, or illicit drug abuse
  • Known and active COVID-19 infection
  • MAC isolate with MIC for clarithromycin ≥ 32 µg/mL at Screening
  • Known hypersensitivity or contraindications to use to ethambutol, azithromycin (including other macrolides or ketolides), or any of their excipients per local labeling guidance.


  • USA050
    Stanford California 94305 United States
  • USA062
    Fresno California 93701-2302 United States


accepting new patients
Start Date
Completion Date
Insmed Incorporated
Sign up for this study
Phase 3 Nontuberculous Mycobacteria Research Study
Study Type
About 99 people participating
Last Updated